Takara Bio, Inc. (4974) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Nihon Kohden Corp.

Asahi Intecc Co., Ltd.

JEOL Ltd.

Sumitomo Bakelite Co., Ltd.

Fukuda Denshi Co., Ltd.

Nakanishi, Inc.

Shimadzu Corp.

Sysmex Corp.

Mani, Inc.

PHC Holdings Corp.

Takara Bio, Inc.

Why is Takara Bio, Inc. ?

With a fall in Net Sales of -41.19%, the company declared Very Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at JPY 3,222 MM
NET SALES(Q) At JPY 9,266 MM has Fallen at -17.71%
PRE-TAX PROFIT(Q) At JPY -1,811 MM has Fallen at -395.07%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -23.89%, its profits have fallen by -14.1%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -23.89% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Takara Bio, Inc. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Takara Bio, Inc.

-25.51%

-0.80

29.69%

Japan Nikkei 225

28.54%

1.14

25.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.44%

EBIT Growth (5y)

-18.45%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.47

Tax Ratio

45.57%

Dividend Payout Ratio

196.64%

Pledged Shares

Institutional Holding

ROCE (avg)

21.86%

ROE (avg)

10.18%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.82

EV to EBIT

28.90

EV to EBITDA

9.70

EV to Capital Employed

0.76

EV to Sales

1.45

PEG Ratio

Dividend Yield

ROCE (Latest)

2.63%

ROE (Latest)

1.23%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

At JPY 1,132.25 MM has Grown at 220.04%

RAW MATERIAL COST(Y)

Fallen by -5.43% (YoY

-27What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at JPY 3,222 MM

NET SALES(Q)

At JPY 9,266 MM has Fallen at -17.71%

PRE-TAX PROFIT(Q)

At JPY -1,811 MM has Fallen at -395.07%

NET PROFIT(Q)

At JPY -1,539 MM has Fallen at -545.66%

DEBT-EQUITY RATIO (HY)

Highest at -11.01 %

INTEREST(Q)

Highest at JPY 117 MM

Here's what is working for Takara Bio, Inc.

Raw Material Cost

Fallen by -5.43% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at JPY 1,360 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (JPY MM)

Here's what is not working for Takara Bio, Inc.

Net Sales

At JPY 9,266 MM has Fallen at -17.71%

over average net sales of the previous four periods of JPY 11,259.75 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit

At JPY -1,811 MM has Fallen at -395.07%

over average net sales of the previous four periods of JPY 613.75 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -1,539 MM has Fallen at -545.66%

over average net sales of the previous four periods of JPY 345.33 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Operating Cash Flow

Lowest at JPY 3,222 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (JPY MM)

Interest

At JPY 117 MM has Grown at 2,240%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest

Highest at JPY 117 MM

in the last five periods and Increased by 2,240% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debt-Equity Ratio

Highest at -11.01 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio